{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T06:37:54Z","timestamp":1768804674129,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer\/Radioth\u00e9rapie"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.canrad.2021.11.007","type":"journal-article","created":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T19:41:29Z","timestamp":1640202089000},"page":"388-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiotherapy of lymphomas"],"prefix":"10.1016","volume":"26","author":[{"given":"J.","family":"Balosso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Missohou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Antoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hennequin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.-A.","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Demoor-Goldschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canrad.2021.11.007_bib0260","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Siegel","year":"2013","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.canrad.2021.11.007_bib0265","series-title":"Survie des patients atteints de cancer en France. \u00c9tude des registres du r\u00e9seau FRANCIM","article-title":"R\u00e9seau Francim","author":"Remontet","year":"2007"},{"key":"10.1016\/j.canrad.2021.11.007_bib0270","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1470-2045(03)01320-2","article-title":"Part II: Hodgkin's lymphoma - diagnosis and treatment","volume":"5","author":"Diehl","year":"2004","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0275","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1200\/JCO.19.00986","article-title":"Long-term follow-up of patients with nodular lymphocyte-predominant Hodgkin lymphoma treated in the HD7 to HD15 trials: a report from the German Hodgkin Study Group","volume":"38","author":"Eichenauer","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0280","doi-asserted-by":"crossref","first-page":"3431","DOI":"10.1200\/JCO.2003.07.131","article-title":"Long-term cause-specific mortality of patients treated for Hodgkin's disease","volume":"21","author":"Aleman","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0285","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2012.44.3721","article-title":"Gonadal function and fertility in survivors after Hodgkin lymphoma treatment within the German Hodgkin Study group HD13 to HD15 trials","volume":"31","author":"Behringer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0290","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s12094-020-02483-8","article-title":"ABVD and BEACOPP regimens\u2019 effects on fertility in young males with Hodgkin lymphoma","volume":"23","author":"Amin","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0295","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1200\/JCO.1987.5.1.27","article-title":"Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy","volume":"5","author":"Santoro","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0300","first-page":"CD007110","article-title":"Chemotherapy alone versus chemotherapy plus radiotherapy for adults with early stage Hodgkin lymphoma","volume":"4","author":"Blank","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.canrad.2021.11.007_bib0305","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1080\/10428194.2020.1725506","article-title":"Consolidation radiotherapy following positron emission tomography complete response in early-stage Hodgkin lymphoma: a meta-analysis","volume":"61","author":"Shaikh","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.canrad.2021.11.007_bib0310","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3324\/haematol.2009.015644","article-title":"Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: a systematic review","volume":"95","author":"Herbst","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.canrad.2021.11.007_bib0315","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.canrad.2021.11.007_bib0320","series-title":"Recommandations SFCE pour le traitement des lymphomes de Hodgkin de l\u2019enfant et de l\u2019adolescent","author":"Martin","year":"2021"},{"key":"10.1016\/j.canrad.2021.11.007_bib0325","doi-asserted-by":"crossref","first-page":"755","DOI":"10.6004\/jnccn.2020.0026","article-title":"NCCN clinical practice guidelines in oncology: hodgkin lymphoma. Version 2.2020","volume":"18","author":"Hoppe","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.canrad.2021.11.007_bib0330","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0335","series-title":"Hematologic malignancies, Hodgkin lymphoma","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-030-32482-7_9","article-title":"Principles of radiotherapy for Hodgkin Lymphoma","author":"Yahalom","year":"2020"},{"key":"10.1016\/j.canrad.2021.11.007_bib0340","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.1995.13.5.1080","article-title":"and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report","volume":"13","author":"Bartlett","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0345","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.ijrobp.2013.05.005","article-title":"Modern radiotherapy for Hodgkin lymphoma: \ufb01eld and dose guidelines from the International lymphoma radiation oncology group (ILROG)","volume":"89","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.007_bib0350","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.ijrobp.2018.01.011","article-title":"the role of radiotherapy in patients with relapsed or refractory Hodgkin Lymphoma: guidelines from the International Lymphoma Radiation Oncology Group","volume":"100","author":"Constine","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.007_bib0355","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.ijrobp.2017.05.007","article-title":"Role of consolidative radiotherapy after autologous hematopoietic cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma","volume":"99","author":"Wilke","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.007_bib0360","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.1998.16.3.818","article-title":"Meta-analysis of chemotherapy versus combined modality treatment trials in Hodgkin's disease","volume":"16","author":"Loef\ufb02er","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0365","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ijrobp.2014.10.042","article-title":"Patterns of relapse from a phase 3 study of response-based therapy for intermediate-risk Hodgkin lymphoma (AHOD0031): a report from the Children's Oncology Group","volume":"92","author":"Dharmarajan","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.007_bib0370","doi-asserted-by":"crossref","first-page":"492","DOI":"10.14338\/IJPT-17-00012","article-title":"Comparing breath hold and free breathing during intensity-modulated radiotherapy and proton therapy in patients with mediastinal Hodgkin lymphoma","volume":"3","author":"Hoppe","year":"2017","journal-title":"Int J Part Ther"},{"key":"10.1016\/j.canrad.2021.11.007_bib0375","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13014-018-1066-2","article-title":"Proton versus photon deep inspiration breath hold technique in patients with Hodgkin lymphoma and mediastinal radiation: a planning comparison of deep inspiration breath hold intensity modulation radiotherapy and intensity modulated proton therapy","volume":"13","author":"Baues","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0380","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/j.ijrobp.2011.05.015","article-title":"Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma","volume":"82","author":"Paumier","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.007_bib0385","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canrad.2016.11.003","article-title":"Respiratory-gated bilateral pulmonary radiotherapy for Ewing's sarcoma and nephroblastoma in children and young adults: dosimetric and clinical feasibility studies","volume":"21","author":"Demoor-Goldschmidt","year":"2017","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2021.11.007_bib0390","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/j.ijrobp.2006.11.008","article-title":"Active breathing control for Hodgkin's disease in childhood and adolescence: feasibility, advantages, and limits","volume":"67","author":"Claude","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.007_bib0395","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.radonc.2020.06.046","article-title":"Involved node radiotherapy in the combined modality treatment for early-stage Hodgkin lymphoma: analysis of relapse location and long-term outcome","volume":"150","author":"Nielsen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0400","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.canrad.2018.07.008","article-title":"Multimodality imaging using PET\/CT (18F)-fluorodeoxyglucose for radiotherapy field delineation of localized Hodgkin lymphoma","volume":"22","author":"\u00c9deline","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.canrad.2021.11.007_bib0405","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.radonc.2008.05.012","article-title":"The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation \ufb01elds. The EORTC-GELA lymphoma group guidelines","volume":"88","author":"Girinski","year":"2008","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0410","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.radonc.2006.05.015","article-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines","volume":"79","author":"Girinski","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0415","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ajog.2020.05.058","article-title":"Counseling and surveillance of obstetrical risks for female childhood, adolescent, and young adult cancer survivors: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group","volume":"224","author":"van der Kooi","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0420","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1748-717X-8-112","article-title":"Contribution of three-dimensional conformal intensity-modulated radiotherapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease","volume":"8","author":"Antoni","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0425","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1080\/0284186X.2018.1512153","article-title":"Comparative treatment planning study for mediastinal Hodgkin's lymphoma: impact on normal tissue dose using deep inspiration breath hold proton and photon therapy","volume":"58","author":"Edvardsson","year":"2019","journal-title":"Acta Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0430","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijrobp.2015.02.030","article-title":"Optimized volumetric arc therapy versus 3D-CRT for early stage mediastinal Hodgkin lymphoma without axillary involvement: a comparison of second cancers and heart disease risk","volume":"92","author":"Filippi","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.canrad.2021.11.007_bib0435","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jama.290.4.465","article-title":"Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease","volume":"290","author":"Travis","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.canrad.2021.11.007_bib0440","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.radonc.2017.06.028","article-title":"Clinical and diagnosis characteristics of breast cancers in women with a history of radiotherapy in the first 30 years of life: a French multicentre cohort study","volume":"124","author":"Demoor-Goldschmidt","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0445","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.critrevonc.2011.01.005","article-title":"Breast cancer occurred after Hodgkin's disease: clinico-pathological features, treatments and outcome: analysis of 214 cases","volume":"81","author":"Cutuli","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0450","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/j.prro.2018.01.007","article-title":"Radiation pneumonitis in pediatric Hodgkin lymphoma patients receiving radiotherapy to the chest","volume":"8","author":"Lewis","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0455","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jnci\/94.3.182","article-title":"Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease","volume":"94","author":"Travis","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.canrad.2021.11.007_bib0460","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose\u2013response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"Van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0465","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study","volume":"37","author":"Bates","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0470","first-page":"12","article-title":"Gender disparity in cardiovascular mortality following radiotherapy for Hodgkin's lymphoma: a systematic review","volume":"6","author":"Khalid","year":"2020","journal-title":"Cardiooncology"},{"key":"10.1016\/j.canrad.2021.11.007_bib0475","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1667\/RR14888.1","article-title":"Hypothyroidism after radiotherapy for childhood cancer: a report from the Childhood Cancer Survivor Study","volume":"190","author":"Inskip","year":"2018","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2021.11.007_bib0480","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11684-020-0752-2","article-title":"Long-term results of suppressing thyroid-stimulating hormone during radiotherapy to prevent primary hypothyroidism in medulloblastoma\/PNET and Hodgkin lymphoma: a prospective cohort study","volume":"15","author":"Massimino","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.canrad.2021.11.007_bib0485","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1667\/RR2240.1","article-title":"Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study","volume":"174","author":"Bhatti","year":"2010","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2021.11.007_bib0490","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1667\/RR15048.1","article-title":"Complete Local and abscopal responses from a combination of radiation and nivolumab in refractory Hodgkin's lymphoma","volume":"190","author":"Qin","year":"2018","journal-title":"Radiat Res"},{"key":"10.1016\/j.canrad.2021.11.007_bib0495","first-page":"2361","article-title":"A pilot investigation on impact of participation in a long-term follow-up clinic (LTFU) on breast cancer and cardiovascular screening among women who received chest radiation for Hodgkin lymphoma","volume":"26","author":"Baxstrom","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.canrad.2021.11.007_bib0500","series-title":"Volume 2\u2013H\u00e9mopathies malignes. \u00c9tude \u00e0 partir des registres des cancers du r\u00e9seau Francim","first-page":"169","article-title":"Estimations nationales de l\u2019incidence et de la mortalit\u00e9 par cancer en France m\u00e9tropolitaine entre 1990 et 2018","author":"Le Guyader-Peyrou","year":"2019"},{"key":"10.1016\/j.canrad.2021.11.007_bib0505","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.clon.2012.07.011","article-title":"Recommendations for the use of radiotherapy in nodal lymphoma","volume":"25","author":"Hoskin","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.canrad.2021.11.007_bib0510","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ijrobp.2014.01.006","article-title":"Modern radiotherapy for nodal non-Hodgkin lymphoma target definition and dose guidelines from the International lymphoma radiation oncology group","volume":"89","author":"Illidge","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Cancer\/Radioth\u00e9rapie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821002961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1278321821002961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T12:35:47Z","timestamp":1761136547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1278321821002961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":51,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1278321821002961"],"URL":"https:\/\/doi.org\/10.1016\/j.canrad.2021.11.007","relation":{},"ISSN":["1278-3218"],"issn-type":[{"value":"1278-3218","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy of lymphomas","name":"articletitle","label":"Article Title"},{"value":"Cancer\/Radioth\u00e9rapie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canrad.2021.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}